Novo Nordisk appoints new CEO, and more people moves for you to know about
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.
Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.
The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.
A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.
Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.
He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.
Drugmakers have flirted with these pilots or partnerships, but few have fully embraced partnerships with digital health startups.
Many healthcare comms leaders are paying close attention to the debate between "access" to healthcare versus making it a requirement, experts say.
Still, pharmaceutical marketers must remember that maintaining regulatory compliance is all-important.
Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
This month we will debut a restyled MM&M logo on our website, in a mobile-friendly, redesigned email newsletter, and on the cover of our magazine.
We, as an industry, frighten rather than inform, cover our butts rather than support, and confuse rather than encourage.
It is also seeking industry input for a new category of honoree, the Top 10 Innovation Catalysts.
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA